PMID- 35990242
OWN - NLM
STAT- MEDLINE
DCOM- 20220823
LR  - 20221207
IS  - 2314-6753 (Electronic)
IS  - 2314-6745 (Print)
VI  - 2022
DP  - 2022
TI  - Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with 
      Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled 
      Clinical Trial in Tianjin, China.
PG  - 4126995
LID - 10.1155/2022/4126995 [doi]
LID - 4126995
AB  - OBJECTIVE: We aimed to clarify the efficacy of dapagliflozin versus liraglutide 
      in patients with overweight or obesity and type 2 diabetes mellitus (T2DM) at the 
      beginning of the coronavirus disease 2019 (COVID-19) pandemic. METHODS: T2DM 
      patients with overweight or obesity who visited the Metabolic Disease Management 
      Center at Tianjin Fourth Central Hospital from October 2019 to January 2020 were 
      recruited and randomised to receive dapagliflozin or liraglutide for 24 weeks. 
      Changes in blood glucose and lipid levels, blood pressure, and body weight, as 
      well as the occurrence of hypoglycaemia and other adverse events, were compared. 
      RESULTS: 309 patients completed the study (143 in liraglutide group and 166 in 
      dapagliflozin group). After 24 weeks, HbA1c, fasting blood glucose (FPG), and 2 h 
      postprandial blood glucose (2hPG) levels significantly decreased from 8.80% +/- 
      1.41% to 7.02% +/- 1.05%, 10.41 +/- 3.13 to 7.59 +/- 2.16 mmol/L, and 17.90 +/- 4.39 to 
      10.12 +/- 2.47 mmol/L, respectively, in the dapagliflozin group, and from 8.92% +/- 
      1.49% to 6.78% +/- 1.00%, 10.04 +/- 2.99 to 7.20 +/- 1.63 mmol/L, and 17.30 +/- 4.39 to 
      10.13 +/- 4.15 mmol/L, respectively, in the liraglutide group. Changes in HbA1c, 
      FPG, and 2hPG levels between groups were not significantly different. Systolic 
      blood pressure (SBP) and low-density lipoprotein cholesterol (LDL-C) level 
      significantly decreased from 144.1 +/- 19.1 to 139.7 +/- 16.2 mmHg (p = 0.001) and 
      from 3.21 +/- 0.94 to 2.98 +/- 0.89 mmol/L (p = 0.014), respectively, in the 
      dapagliflozin group. After COVID-19 outbreak, the number of patients taking 
      sleep-promoting drugs increased from 4.9% to 9.4% (p = 0.029). CONCLUSIONS: 
      Liraglutide and dapagliflozin had strong hypoglycaemic effects in patients with 
      overweight or obesity and T2DM at the beginning of the COVID-19 pandemic. 
      Dapagliflozin may be beneficial in improving SBP and LDL-C levels; however, 
      further research is warranted.
CI  - Copyright (c) 2022 Hao Zhaohu et al.
FAU - Zhaohu, Hao
AU  - Zhaohu H
AUID- ORCID: 0000-0002-3965-3805
AD  - Department of Metabolic Disease Management Center, Tianjin 4th Central Hospital, 
      300140 Tianjin, China.
FAU - Xiao, Huang
AU  - Xiao H
AD  - NHC Key Laboratory of Hormones and Development (Tianjin Medical University), 
      Tianjin Key Laboratory of Metabolic Diseases, Tianjin Medical University Chu 
      Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin 300134, 
      China.
FAU - Hailin, Shao
AU  - Hailin S
AUID- ORCID: 0000-0003-3279-9542
AD  - Department of Metabolic Disease Management Center, Tianjin 4th Central Hospital, 
      300140 Tianjin, China.
FAU - Feng, He
AU  - Feng H
AUID- ORCID: 0000-0003-3286-8309
AD  - Department of Cardiology, Tianjin 4th Central Hospital, 300140 Tianjin, China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20220813
PL  - England
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Blood Glucose)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Glucosides)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 1ULL0QJ8UC (dapagliflozin)
RN  - 839I73S42A (Liraglutide)
SB  - IM
MH  - Benzhydryl Compounds
MH  - Blood Glucose/metabolism
MH  - COVID-19
MH  - Cholesterol, LDL
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Glucosides
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - *Hypoglycemic Agents/therapeutic use
MH  - *Liraglutide/therapeutic use
MH  - Obesity/complications/drug therapy
MH  - *Overweight/complications/drug therapy
MH  - Pandemics
MH  - *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
MH  - Treatment Outcome
PMC - PMC9381852
COIS- The authors declare that they have no competing interests.
EDAT- 2022/08/23 06:00
MHDA- 2022/08/24 06:00
PMCR- 2022/08/13
CRDT- 2022/08/22 03:52
PHST- 2022/04/25 00:00 [received]
PHST- 2022/07/13 00:00 [accepted]
PHST- 2022/08/22 03:52 [entrez]
PHST- 2022/08/23 06:00 [pubmed]
PHST- 2022/08/24 06:00 [medline]
PHST- 2022/08/13 00:00 [pmc-release]
AID - 10.1155/2022/4126995 [doi]
PST - epublish
SO  - J Diabetes Res. 2022 Aug 13;2022:4126995. doi: 10.1155/2022/4126995. eCollection 
      2022.